New spinal injury drug gets first human safety test
NCT ID NCT05739734
First seen Feb 03, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This early-stage trial tests whether a single dose of CRIS100 is safe for people with a recent thoracic spinal cord injury. Five adults aged 18-70 will receive the drug directly at the injury site within 72 hours of their accident. The study focuses on side effects and lab changes, while also checking if the treatment helps improve nerve function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THORACIC SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.